New research using brain imaging technology helps to clarify how psilocybin — the psychoactive ingredient in magic mushrooms — affects the brain, perhaps paving the way for therapeutic use of the substance as an adjunct to psychotherapy.
Dr. Robin Carhart-Harris, from the Department of Medicine at Imperial College London, the first author of two new papers, said, “Psilocybin was used extensively in psychotherapy in the 1950s, but the biological rationale for its use has not been properly investigated until now.”
In the first study, published in Proceedings of the National Academy of Sciences (PNAS), 30 healthy volunteers had psilocybin infused into their blood while inside magnetic resonance imaging (MRI) scanners, which measure changes in brain activity.
The scans showed that activity decreased in “hub” regions of the brain, areas that are especially well-connected with other areas.
The second study, published online by the British Journal of Psychiatry, found that psilocybin enhanced volunteers’ recollections of personal memories, which the researchers suggest could make it useful as an adjunct to psychotherapy.
Dr. David Nutt, professor of neuropsychopharmacology and senior author of both studies, said, “Psychedelics are thought of as ‘mind-expanding’ drugs so it has commonly been assumed that they work by increasing brain activity, but surprisingly, we found that psilocybin actually caused activity to decrease in areas that have the densest connections with other areas.
“These hubs constrain our experience of the world and keep it orderly. We now know that deactivating these regions leads to a state in which the world is experienced as strange.”
The intensity of the effects reported by the participants, including visions of geometric patterns, unusual bodily sensations, and altered sense of space and time, correlated with a decrease in oxygenation and blood flow in certain parts of the brain.
The function of these areas, the medial prefrontal cortex (mPFC) and the posterior cingulate cortex (PCC), is the subject of debate among neuroscientists, but the PCC is proposed to have a role in consciousness and self-identity.
Similarly, psilocybin reduced blood flow in the hypothalamus, where blood flow is increased during cluster headaches, perhaps explaining why some sufferers have said symptoms improved under psilocybin.
In the BJP study, 10 volunteers viewed written cues that prompted them to think about memories associated with strong positive emotions while inside the brain scanner.
The participants rated their recollections as being more vivid after taking psilocybin compared with a placebo, and with psilocybin there was increased activity in areas of the brain that process vision and other sensory information.
Participants were also asked to rate changes in their emotional wellbeing two weeks after taking the psilocybin and placebo.
Their ratings of memory vividness under the drug showed a significant positive correlation with wellbeing two weeks afterwards.
In a previous study of 12 people in 2011, researchers found that people with anxiety who were given a single psilocybin treatment had decreased depression scores six months later.
“Our findings support the idea that psilocybin facilitates access to personal memories and emotions,” Carhart-Harris said.
Previous studies have suggested that psilocybin can improve people’s sense of emotional wellbeing and even reduce depression in people with anxiety.
“This is consistent with our finding that psilocybin decreases mPFC activity, as many effective depression treatments do. The effects need to be investigated further, and ours was only a small study, but we are interested in exploring psilocybin’s potential as a therapeutic tool,” he said.
Nevertheless, the researchers acknowledged that because the participants in this study had volunteered after having previous experience of psychedelics, they may have held prior assumptions about the drugs which could have contributed to the positive memory rating and the reports of improved wellbeing in the follow-up
Functional MRI measures brain activity indirectly by mapping blood flow or the oxygen levels in the blood. When an area becomes more active, it uses more glucose, but generates energy in rapid chemical reactions that do not use oxygen.
Consequently, blood flow increases but oxygen consumption does not, resulting in a higher concentration of oxygen in blood in the local veins.
In the PNAS study, the volunteers were split into two groups, each studied using a different type of fMRI: 15 were scanned using arterial spin labeling (ASL) perfusion fMRI, which measures blood flow, and 15 using blood-oxygen level-dependent (BOLD) fMRI.
The two modalities produced similar results, strongly suggesting that the observed effects were genuine.
The studies were carried out using protocol for licensed storeage and handling of a schedule I drug and were approved by NHS research ethics committees.
All the volunteers were mentally and physically healthy and had taken hallucinogenic drugs previously without any adverse response.
The research involved scientists from Imperial, the University of Bristol and Cardiff University and was funded by the Beckley Foundation, the Neuropsychoanalysis Foundation, Multidisciplinary Association for Psychedelic Studies, and the Heffter Research Institute.